Since the first stem cell transplant occurred more than 65 years ago (1957), there has been a nearly exponential increase in stem cell transplants, and in late 2012, the millionth stem cell transplant occurred, a landmark event in stem cell medicine. It is clear that the stem cells contained within cord blood banking now have the potential to improve and save lives. Since the first cord blood transplant was performed in 1988, stem cells derived from umbilical blood have been used in more than 40,000 transplants worldwide. [Read more…]
EV Biologics Completes Production of Cutting-Edge MSC Exosome-Based Therapeutic
TAMPA, FL – EV Biologics Corp, OTC PINK:YECO, announced that it has completed production of a next-generation, “Gen-2”, MSC exosome-based therapeutic product.
Rigorous product analysis has already begun, and the Company has engaged leading independent testing laboratories to perform sophisticated analyses of molecular composition, therapeutic activity, and any potential forms of contamination, to thoroughly validate the product and prepare comprehensive product data specifications that are second to none. [Read more…]
New Study Reveals Breakthrough in Epidermal Regeneration Using Mesenchymal Stem Cell Extracellular Vesicles and Ronawk’s Bio-Blocks™
Overland Park, KS – In a groundbreaking development, a recent peer-reviewed paper titled “Mesenchymal Stem Cell Extracellular Vesicles from Tissue-Mimetic System Enhance Epidermal Regeneration via Formation of Migratory Cell Sheets,” published on July 29, 2023, in the journal “Tissue Engineering and Regenerative Medicine,” offers open access to its findings. [Read more…]
Revolutionary Study Introduces Advanced Approach to Epidermal Regeneration Using Mesenchymal Stem Cell Secretome and Ronawk’s Bio-Blocks™
Overland Park, KS – A groundbreaking study titled “Tailoring the Secretome Composition of Mesenchymal Stem Cells to Augment Specific Functions of Epidermal Regeneration: An In Vitro Diabetic Model,” conducted by, Jacob G. Hodge, Ph.D., introduces a pioneering strategy to revolutionize epidermal regeneration using the secretome of mesenchymal stem cells (MSCs) utilizing Ronawk’s Bio-Blocks™. Published in June 2023 in the journal
“Frontiers in Medical Technology” and available through open access, the study unveils a powerful solution for optimizing wound healing, particularly in a diabetic context. [Read more…]
Neobiosis Announces FDA Approval of IND for Use of ViXomeTM in COVID-19 ‘Post Covid Syndrome’
GAINESVILLE, Fla., – Neobiosis, is a leading research and manufacturing biotechnology company focused on pioneering the development of novel therapeutics from perinatal tissues as a new class of medicines. Today, Neobiosis announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for ViXome™, its drug for the treatment of ‘Post COVID Syndrome (AKA “Long Haul COVID Syndrome”). [Read more…]
- « Previous Page
- 1
- …
- 123
- 124
- 125
- 126
- 127
- …
- 339
- Next Page »